References
1. EMA website, "Partners & Networks,"
http://www.ema.europa.eu/, accessed 7 Sept. 2012.
2. EMA website, "Road Map to 2015,"
http://www.ema.europa.eu/, accessed 7 Sept. 2012.
3. K. Tadano, "PMDA's International Strategic Plan and its Implementation" (PMDA website),
http://www.pharm.kitasato-u.ac.jp/, accessed 7 Sept. 2012.
4. Centre for Innovation in Regulatory Science (CIRS) website, "May 2012 Slide of the Month," http://cirsci.org/, accessed 7 Sept. 2012.
5. EMA website, "Report on interactions between the Japanese Ministry of Health, Labour and Welfare (MHLW)/Pharmaceuticals
and Medical Devices Agency (PMDA) and the European Medicines Agency (EMA),"
http://www.ema.europa.eu/, accessed 7 Sept. 2012.
6. Y. Hayashi, "EU, USA and Japan (II)– Reports from Regulators on Exchange Assignments" (PMDA website),
http://www.pmda.go.jp/, accessed 7 Sept. 2012.
7. EMA website, "European Union — Japan orphan medicines cooperation".
http://www.ema.europa.eu/, accessed 7 Sept. 2012.
8. EC website, "Medicines Regulation: Transatlantic Administrative Simplification Action Plan," http://ec.europa.eu/, accessed 7 Sept. 2012.
9. EMA website, "Enhancing GMP Inspection Cooperation Between the EMA and FDA,"
http://www.ema.europa.eu/, accessed 10 Sept. 2012.
10. WHO website, "Essential medicines for children".
http://www.who.int/, accessed 7 Sept. 2012.
11. E. Silverman, "Clinical Trial Deaths In India Dropped" (Pharmalot website, 2012),
http://www.pharmalot.com/, accessed 7 Sept. 2012.
|
